1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

 
• By Mandy Jackson

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Finance Watch
Cortexyme, Milestone and NextCure deliver double-digit returns.

After just 13 biopharmaceutical companies went public in the US during the first four months of 2019, setting a pace of about three per month, five drug developers launched initial public offerings on 7 and 8 May – with mixed results.

Trevi Therapeutics Inc. began the flurry of IPO launches on 7 May, while the other four launched on 8...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks

 
• By Mandy Jackson

Public Company Edition: The US jobs report for August hurt the S&P 500 and Dow Jones, but the XBI rose 2.2% and is up 6% year-to-date. Despite signs of life, with a recent small IPO from Curanex and a larger one proposed by LB Pharmaceuticals, fundraising was down in Q2.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Finance Watch: Treeline Emerges From The Shadows With $200m, Bringing Total To $1.1bn

 
• By Mandy Jackson

Private Company Edition: Treeline will fund Phase I trials for at least four cancer drugs with its $200m series A extension. Also, allogeneic CAR-T developer Wugen raised $115m, CHARM Therapeutics garnered $80m in series B cash and Plexium disclosed a $60.1m financing.

Mineralys In The Money As Lorundrostat Gets Close To Market

 
• By Kevin Grogan

An upsized public offering will add $250m to the company’s coffers.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.